Abstract
Mastitis remains a major concern of the dairy industry, despite frequent use of therapy and application of mastitis control programs. Prevention and control are the most productive approaches to mastitis. However, therapy is important for clinical mastitis and is a component of mastitis control. Approximately 20-80% of cows are affected by clinical mastitis annually (Dohoo, 1987, Wilesmith et al., 1986). The annual US market for intramammary infusion products is approximately $30 million (Gingerich, 1987). Mastitis therapy should be efficacious, cost-effective, and antibiotic residues in meat and milk should be avoided. The purpose of this paper is to discuss mastitis therapy and the pharmacology of drugs in the bovine mammary gland.Specific areas considered include:1. Current status of mastitis.2. The pharmacology of drugs in the mammary gland.3. Therapeutic failures.4. Current developments in mastitis therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Association of Bovine Practitioners Conference Proceedings
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
